drugset / Trial / NCT06704685
A Randomized Controlled Trial on the Efficacy and Safety of Butylphthalide in Reducing Myocardial Infarction Size and Improving Outcomes in STEMI Patients After Primary PCI
Phase 3
Not yet recruiting
40 enrolled
Xiangya Hospital of Central South University
CSPC Pharmaceutical Group Limited · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This study is a prospective, randomized, placebo-double-blind, multicenter clinical trial. The purpose of this study is to investigate whether "butylphthalide +PCI" combined treatment mode on the basis of traditional drug therapy could reduce myocardial infarct size, improve cardiac function and long-term prognosis of patients with acute myocardial infarction, and verify the drug safety of butylphthalide in the treatment of STEMI within the window period of 12 hours.
Timeline
- Start
- 2024-12-01
- Primary completion
- 2025-10-01
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Butylphthalide | Small molecule | 2 unknown | — |